ASH 2018 highlights in myeloma
Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in…
Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in…
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States)…
Data from the phase III MAIA clinical trial was presented yesterday as part of the Late-Breaking Abstracts Session during the 60th American Society of Hematology (ASH) Annual Meeting in San Diego.
Initial data from the ongoing phase I clinical trial of bb21217 (CRB-402) were presented at the 60th Annual Meeting of the American Society of Hematology (ASH). This is an investigational next-generation anti-BCMA CAR T cell…
A collaboration between patient advocates and pharmaceutical companies usually requires both parties to sign contracts for different engagements such as for advisory, consultancy, collaborative or speaker engagements. These contracts usually cover areas such as confidentiality,…
The annual meeting of the American Society of Haematology (ASH) 2018 starts this week (between 1 and 4 December) in San Diego, California.
European Society for Medical Oncology (ESMO), Munich (Germany) – Some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer drugs following their approval…
Complementary and alternative medicines are used by 1 in 2 patients before and during cancer treatments, however they are frequently associated with drug-drug interactions, a estudy at ESMO 2018 report.